# DMRA — Damora Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** DMRA  
**Sources:** 22  
**Published:** 2026-10-25  
**Canonical:** https://app.k3vl4r.com/research/deep-research-dmra-damora-therapeutics-inc-catalysts-narrative-risks-9048

---

# Damora Therapeutics, Inc. (NASDAQ: DMRA) — Research Summary (as of October 25, 2026)

Below is a synthesis of primary-company disclosures, analyst commentary, and market data. This is not investment advice.

## Current Snapshot
- Last close **$21.09** on October 23, 2026; market cap **~$1.30B**; Beta **1.43**; EPS (TTM) **-0.25**; net income (TTM) **-241.25M**; total cash **~$540.52M** [[16]](https://finance.yahoo.com/quote/DMRA/).
- 52-week range: **$16.50** (March 20, 2026) to **$34.89** (July 20, 2026) [[9]](https://stockscan.io/stocks/DMRA/price-history), [[20]](https://finance.yahoo.com/quote/DMRA/history/).
- Company: a Massachusetts-based biotech developing subcutaneous biologics for mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (ET and MF), with lead asset **DMR-001** [[5]](https://seekingalpha.com/article/4946386-damora-therapeutics-potential-payday-is-a-long-way-off), [[22]](https://damoratx.com/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-dmra-damora-therapeutics-inc-catalysts-narrative-risks-9048 (free to sign up)._
